Latest Generation Random Analyzer System Unveiled at the AACC Clinical Lab Expo
|
By LabMedica International staff writers Posted on 01 Aug 2013 |

Image: The Siemens VersaCell X3 System (Photo courtesy of Siemens).
The latest generation random access clinical chemistry and immunochemistry analyzer is receiving its debut at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.
The Siemens Healthcare Diagnostics (Tarrytown, NY, USA) is unveiling the advanced VersaCell X3 system at the Clinical Lab Expo.
The newest model of Siemens’s longstanding VersaCell System, the new VersaCell X3 Solution now offers the benefits of automation without the space or budget considerations of a track-based system. VersaCell X3 Solution’s arrival compliments the recent launch of the Siemens Aptio Automation platform, designed for the growing needs of medium- to very high-volume laboratories.
The VersaCell X3 Solution delivers several advantages. The new platform maintains its small footprint and upright design, but now connects up to three Siemens analyzers through a single robotic sample interface for increased productivity gains. By supporting a customized mix of chemistry, immunoassay and/or integrated systems and associated assay menus, VersaCell X3 Solution helps labs to reduce operator sample handling, better prioritize staff work and eliminate pre- and post-analytical processing—all through one-touch sample management.
A new priority drawer on the VersaCell X3 Solution provides eight new STAT positions and frees up 50 sample positions for routine processing, enhancing STAT management and increasing overall sample routing flexibility. Modifications to VersaCell X3 Solution’s signature robotic arm also enable it to support both rounded and flat-bottom tubes, and the incorporation of a docking plate reduces service intervention time for all connected systems. A centralized screen on VersaCell X3 Solution provides consolidated, single-operator access to all connected analyzers, and further data consolidation is achievable through a connection to Siemens’ CentraLink Data Management System.
“Siemens strives to be a trusted partner for labs of all sizes and central to that goal is helping them identify and capitalize on their workflow excellence potential,” said Dave Hickey, CEO of the IT Business Unit at Siemens Healthcare Diagnostics. “The introduction of VersaCell X3 Solution is yet another way Siemens delivers on this mission through its ability to help labs streamline nonautomated environments and enhance operational efficiency, all at a cost they can justify.”
Related Links:
Siemens Healthcare Diagnostics
The Siemens Healthcare Diagnostics (Tarrytown, NY, USA) is unveiling the advanced VersaCell X3 system at the Clinical Lab Expo.
The newest model of Siemens’s longstanding VersaCell System, the new VersaCell X3 Solution now offers the benefits of automation without the space or budget considerations of a track-based system. VersaCell X3 Solution’s arrival compliments the recent launch of the Siemens Aptio Automation platform, designed for the growing needs of medium- to very high-volume laboratories.
The VersaCell X3 Solution delivers several advantages. The new platform maintains its small footprint and upright design, but now connects up to three Siemens analyzers through a single robotic sample interface for increased productivity gains. By supporting a customized mix of chemistry, immunoassay and/or integrated systems and associated assay menus, VersaCell X3 Solution helps labs to reduce operator sample handling, better prioritize staff work and eliminate pre- and post-analytical processing—all through one-touch sample management.
A new priority drawer on the VersaCell X3 Solution provides eight new STAT positions and frees up 50 sample positions for routine processing, enhancing STAT management and increasing overall sample routing flexibility. Modifications to VersaCell X3 Solution’s signature robotic arm also enable it to support both rounded and flat-bottom tubes, and the incorporation of a docking plate reduces service intervention time for all connected systems. A centralized screen on VersaCell X3 Solution provides consolidated, single-operator access to all connected analyzers, and further data consolidation is achievable through a connection to Siemens’ CentraLink Data Management System.
“Siemens strives to be a trusted partner for labs of all sizes and central to that goal is helping them identify and capitalize on their workflow excellence potential,” said Dave Hickey, CEO of the IT Business Unit at Siemens Healthcare Diagnostics. “The introduction of VersaCell X3 Solution is yet another way Siemens delivers on this mission through its ability to help labs streamline nonautomated environments and enhance operational efficiency, all at a cost they can justify.”
Related Links:
Siemens Healthcare Diagnostics
Latest AACC 2013 News
- Beckman Coulter Launches Newest Version of Remisol Advance at AACC
- Beckman Coulter's New Solutions Demonstrated at 2013 AACC Annual Meeting
- Solutions Designed for Labs to Reduce Costs and Improve Productivity Showcased at the AACC Expo
- Ultrasensitive Troponin-I Assay to Be Introduced at the AACC Clinical Lab Expo
- Customized Assays Assembled Using Digital Molecular Barcoding Chemistry
- Customized Monoclonal Antibody Design Highlighted at the AACC Clinical Lab Expo
- Advanced Hospital Robot Courier Debuts at the AACC Clinical Lab Expo
- Researchers Will Have Ready Access to Molecular Diagnostics Expertise at the AACC Clinical Lab Expo
- Hybrid Random Access Analyzer on Display at AACC's Clinical Lab Expo
- DCN Diagnostics and Asahi Kasei Fibers Launch Market Collaboration
- Quantitative Test for ß-Hydroxybutyrate Assesses Diabetic Ketoacidosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








